Brown Advisory’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Brown Advisory’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,029	Closed	-$185K	–	1264
2023 Q1	$185K	Hold	15,029	–	–	﹤0.01%	1144
2022 Q4	$172K	Hold	15,029	–	–	﹤0.01%	1144
2022 Q3	$56K	Hold	15,029	–	–	﹤0.01%	1111
2022 Q2	$89K	Hold	15,029	–	–	﹤0.01%	1076
2022 Q1	$95K	Hold	15,029	–	–	﹤0.01%	1089
2021 Q4	$59K	Hold	15,029	–	–	﹤0.01%	1222
2021 Q3	$73K	Hold	15,029	–	–	﹤0.01%	1089
2021 Q2	$96K	Hold	15,029	–	–	﹤0.01%	1052
2021 Q1	$94K	Hold	15,029	–	–	﹤0.01%	1063
2020 Q4	$104K	Hold	15,029	–	–	﹤0.01%	997
2020 Q3	$60K	Hold	15,029	–	–	﹤0.01%	948
2020 Q2	$50K	Hold	15,029	–	–	﹤0.01%	931
2020 Q1	$32K	Hold	15,029	–	–	﹤0.01%	924
2019 Q4	$47K	Hold	15,029	–	–	﹤0.01%	1027
2019 Q3	$68K	Sell	15,029 -4,073	-21%	-$20.4K	﹤0.01%	984
2019 Q2	$91K	Hold	19,102	–	–	﹤0.01%	1002
2019 Q1	$104K	Hold	19,102	–	–	﹤0.01%	1281
2018 Q4	$58K	Sell	19,102 -1,271	-6%	-$4.41K	﹤0.01%	1221
2018 Q3	$85K	Sell	20,373 -5,084	-20%	-$21.4K	﹤0.01%	1300
2018 Q2	$98K	Hold	25,457	–	–	﹤0.01%	1251
2018 Q1	$161K	Hold	25,457	–	–	﹤0.01%	1120
2017 Q4	$205K	Hold	25,457	–	–	﹤0.01%	1159
2017 Q3	$291K	Hold	25,457	–	–	﹤0.01%	1016
2017 Q2	$248K	Hold	25,457	–	–	﹤0.01%	1075
2017 Q1	$617K	Sell	25,457 -1,271	-5%	-$31.8K	﹤0.01%	755
2016 Q4	$858K	Hold	26,728	–	–	﹤0.01%	662
2016 Q3	$1.33M	Hold	26,728	–	–	﹤0.01%	558
2016 Q2	$1.13M	Hold	26,728	–	–	﹤0.01%	582
2016 Q1	$1.76M	Hold	26,728	–	–	0.01%	488
2015 Q4	$1.66M	Hold	26,728	–	–	0.01%	495
2015 Q3	$1.79M	Sell	26,728 -954	-3%	-$77.9K	0.01%	484
2015 Q2	$2.69M	Sell	27,682 -1,650	-6%	-$157K	0.01%	413
2015 Q1	$2.74M	Buy	+29,332	New	+$2.5M	0.01%	423
2014 Q3	–	Sell	-3,936	Closed	-$226K	–	981
2014 Q2	$226K	Sell	3,936 -1,968	-33%	-$99.9K	﹤0.01%	868
2014 Q1	$234K	Sell	5,904 -8,859	-60%	-$379K	﹤0.01%	840
2013 Q4	$619K	Hold	14,763	–	–	﹤0.01%	604
2013 Q3	$440K	Hold	14,763	–	–	﹤0.01%	647
2013 Q2	$783K	Buy	+14,763	New	+$647K	﹤0.01%	512

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Brown Advisory's MACK Position: Q2 2023 in Review

Brown Advisory sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2023, closing a stake of 15,029 shares — an estimated $185K sold.

Brown Advisory first reported a position in MACK in Q2 2013 and held it in 38 quarters. The position peaked at $2.74M in Q1 2015. 62 funds tracked by Wall St. Rank hold MACK as of Q2 2023.

Brown Advisory reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Brown Advisory sold 15,029 Merrimack Pharmaceuticals, Inc. shares in Q2 2023, an estimated $185K.
Brown Advisory first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 38 quarters.
Brown Advisory's Merrimack Pharmaceuticals, Inc. position peaked at $2.74M in Q1 2015.
62 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2023.

Based on Brown Advisory's 13F filing for Q2 2023, filed 31 Jul 2023.